Bayesian adaptive randomization designs for targeted agent development.
about
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewMethods for identification and confirmation of targeted subgroups in clinical trials: A systematic reviewHyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain BarrierAdaptive adjustment of the randomization ratio using historical control data.Bayesian predictive modeling for genomic based personalized treatment selection.Fool's gold, lost treasures, and the randomized clinical trial.Clinical trial designs for testing biomarker-based personalized therapies.Simulation study for evaluating the performance of response-adaptive randomization.Randomized phase II trials: a long-term investment with promising returnsAdaptive clinical trial designs in oncology.Evaluating many treatments and biomarkers in oncology: a new designA Dirichlet process mixture model for survival outcome data: assessing nationwide kidney transplant centers.Innovative Clinical Trial Designs: Toward a 21st-Century Health Care SystemCommentary on Hey and KimmelmanEvaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncologyA 2-stage phase II design with direct assignment option in stage II for initial marker validation.Study designs and statistical analyses for biomarker researchClinical trial designs incorporating predictive biomarkers.Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.Phase II trial design with Bayesian adaptive randomization and predictive probability.Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.Integrating biomarkers in clinical trials.Prediction-Oriented Marker Selection (PROMISE): With Application to High-Dimensional Regression.Adaptive Clinical Trials: Overview of Early-Phase Designs and Challenges.A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.Bayesian response adaptive randomization using longitudinal outcomes.Worth adapting? Revisiting the usefulness of outcome-adaptive randomization.Unbiased estimation for response adaptive clinical trials.A Bayesian adaptive design for biomarker trials with linked treatments.Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancerIt's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes.Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.Adding experimental arms to platform clinical trials: randomization procedures and interim analyses.Bayesian response-adaptive designs for basket trials.
P2860
Q26766584-51430B38-DF23-49B8-AAE7-0A2D78D85EEEQ28086970-BD3C4551-0160-4C99-85A1-53963918FB9DQ28550363-13079261-FB44-4035-80AE-D4001B6CA9F1Q30629562-6BC855FB-A793-4F5F-93DC-F61299434B9AQ30758322-D6B83718-EBCF-439F-8326-FAE9E9AAFF7AQ34669260-8589605F-87FC-4C4C-ABBA-C30510402F10Q34977663-0108CA1F-A3E7-4A7C-83CE-F345B9732094Q35040143-0BED84C1-34F2-45F8-BAA9-5EF14BEC98ADQ35115259-2469D4C5-1CE9-46D1-A421-E5471EB7C246Q35206844-62808332-D498-457B-A20C-518D2A962AC5Q35379179-0FBAD8A5-DF41-417B-AAA1-AF4AB34C9A66Q35549059-19B240F8-9B1A-4922-8060-A4A7D3DF56BBQ35797280-79092065-8811-4607-93E4-DD7761E1808EQ35820701-E391188F-187D-4703-B6DB-3567229FA409Q36036648-FB254CB2-4A8A-4364-8EA8-ED80A0B20623Q36170160-F46E47F2-1EFE-44AC-8188-E7A355195724Q36239075-EB5F4B6D-BC05-4AB6-ADFA-262FEFF45070Q36534713-FA2469F9-44B0-4538-AD1F-90EE7783C2D4Q37238720-FAE12A9A-F80D-410B-BA3F-77917118F462Q37320508-0D58602B-BDA8-4FDA-9375-21B8521C2859Q37731264-FAA20D2C-ED63-4A44-B9DE-1718C8233146Q37853183-A93D050B-B07C-4D0B-B658-38D13236BA6AQ38635859-18DBAC56-4283-4C57-8E75-A53305736B9DQ38697445-3343300F-4796-4731-88B5-1DCB369604FBQ39273219-03637F21-6A75-4180-95F0-E0005A27865DQ40811033-78EC1124-9793-482C-B4BC-2069B39E2691Q41220055-E388EB60-FF8C-4D28-8C93-64626CD3D8CFQ41490570-1062B39D-437D-48A9-9E6C-72540F9B4951Q41835806-CD4ABDF7-DF52-4242-9B99-057B784C0EB1Q42322498-F9EC79FE-4A72-4E19-ADBE-3F04823B40CDQ42582344-56D89A37-F4BD-46EB-A946-293E9E2C0E47Q43055307-0BE1EA12-1475-4846-9E28-A9AAFF144865Q45304949-03084B22-D96E-4C1E-8FB8-1A075DE9EB3FQ47363292-800A28D3-FB9E-41E9-B68C-300F943C8CF4
P2860
Bayesian adaptive randomization designs for targeted agent development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bayesian adaptive randomization designs for targeted agent development.
@en
Bayesian adaptive randomization designs for targeted agent development.
@nl
type
label
Bayesian adaptive randomization designs for targeted agent development.
@en
Bayesian adaptive randomization designs for targeted agent development.
@nl
prefLabel
Bayesian adaptive randomization designs for targeted agent development.
@en
Bayesian adaptive randomization designs for targeted agent development.
@nl
P2093
P2860
P356
P1433
P1476
Bayesian adaptive randomization designs for targeted agent development.
@en
P2093
P2860
P304
P356
10.1177/1740774510373120
P577
2010-06-22T00:00:00Z